北京天坛生物制品股份有限公司第九届董事会第二十七次会议决议公告

Core Viewpoint - The company held its 27th meeting of the 9th Board of Directors, where several key resolutions were passed regarding capital increases and governance document revisions [1][3][5][7][9][11]. Group 1: Capital Increases - The company approved a capital increase of 10 million yuan for Tangyue Ruide Plasma Station, raising its registered capital from 10 million yuan to 20 million yuan, with Tangyue Ruide holding 100% equity [1]. - A capital increase of 7 million yuan was approved for Luotian Ruide Plasma Station, increasing its registered capital from 1 million yuan to 8 million yuan, with Tangyue Ruide also holding 100% equity [3]. Group 2: Share Transfer - The company approved the public transfer of 100% equity in Shanghai Shangsheng Biological Products Co., Ltd. for no less than 15.5 million yuan through a designated property transaction agency [5]. Group 3: Governance Document Revisions - The company approved revisions to the General Manager Office Meeting Rules [7]. - The company approved revisions to the Related Party Transaction Management System [9]. - The company approved revisions to the Comprehensive Risk Management Measures [11].